Review reports adverse event management in liver cancer patients receiving radioembolization, highlighting strategies to prevent and mitigate toxicities.
Transarterial radioembolization using yttrium-90 (Y-90) microspheres is an important therapy in the management of unresectable primary liver tumors or hepatic metastases. While radioembolization is generally well-tolerated, it is not free from adverse events, and familiarity with the prevention and treatment of radioembolization-specific complications is an important component of patient care. This article aims to review radioembolization-specific toxicities stratified by hepatic, extrahepatic, and systemic effects, with a focus on preventing and mitigating radioembolization-induced morbidity.
No takes yet. Share an insight, caveat, or question.
Laidlaw et al. (2021) studied this question.